AbbVie Collaborated with Anima Biotech to Discover and Develop mRNA Biology Modulators
Shots:
- Anima will receive $42M up front, ~$540M in option fees and R&D milestones across 3 targets & is also eligible for commercial milestones along with royalties on net sales
- AbbVie gets an option to expand the collaboration with ~3 additional targets & also holds an exclusive right to license and further develop and commercialize the programs
- The companies collaborated to discover novel mRNA biology modulators against the collaboration targets using Anima's mRNA Lightning technology platform and AbbVie's extensive expertise in oncology and immunology. The collaboration also helps to strengthen AbbVie's capabilities in discovering and developing drugs
Ref: AbbVie | Image: AbbVie
Related News:- AbbVie’s Vraylar (cariprazine) Receives the US FDA’s Approval as an Adjunctive Treatment for Major Depressive Disorder
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
